Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Obesity Reports
Published in: Current Obesity Reports 1/2017

01-03-2017 | ETIOLOGY OF OBESITY (T GILL, SECTION EDITOR)

Viral Infections and Obesity

Authors: Jameson D. Voss, Nikhil V. Dhurandhar

Published in: Current Obesity Reports | Issue 1/2017

Login to get access

Abstract

Purpose of review

Obesity is a multifactorial disease that is now endemic throughout most of the world. Although addressing proximate causes of obesity (excess energy intake and reduced energy expenditure) have been longstanding global health priorities, the problem has continued to worsen at the global level.

Recent findings

Numerous microbial agents cause obesity in various experimental models—a phenomena known as infectobesity. Several of the same agents alter metabolic function in human cells and are associated with human obesity or metabolic dysfunction in humans. We address the evidence for a role in the genesis of obesity for viral agents in five broad categories: adenoviridae, herpesviridae, phages, transmissible spongiform encephalopathies (slow virus), and other encephalitides and hepatitides. Despite the importance of this topic area, there are many persistent knowledge gaps that need to be resolved.

Summary

We discuss factors motivating further research and recommend that future infectobesity investigation should be more comprehensive, leveraged, interventional, and patient-centered.
Literature
1.
Dhurandhar EJ, Keith SW. The aetiology of obesity beyond eating more and exercising less. Best Pract Res Clin Gastroenterol. 2014;28(4):533–44.PubMedCrossRef
2.
• Voss JD, Atkinson RL, Dhurandhar NV. Role of adenoviruses in obesity. Rev Med Virol. 2015;25(6):379–87. Recent review of several viral etiologies of obesity, including a review of adenoviridea seroprevalence, and homology of E4-ORF-1 with Ad-36.PubMedCrossRef
3.
• Sanchez EL, Lagunoff M. Viral activation of cellular metabolism. Virology. 2015;479-480:609–18. Reviews numerous viruses that alter cellular metabolism and are lipogenic.PubMedCrossRef
4.
Cheng J, Ke Q, Jin Z, Wang H, Kocher O, Morgan JP, et al. Cytomegalovirus infection causes an increase of arterial blood pressure. PLoS Pathog. 2009;5(5):e1000427.PubMedPubMedCentralCrossRef
5.
Hamer M, Batty GD, Kivimäki M. Obesity, metabolic health, and history of cytomegalovirus infection in the general population. J Clin Endocrinol Metab. 2016;101(4):1680–5.PubMedCrossRef
6.
Ridaura VK, Faith JJ, Rey FE, Cheng J, Duncan AE, Kau AL, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science. 2013;341(6150):1251214.CrossRef
7.
Mills S, Shanahan F, Stanton C, Hill C, Coffey A, Ross RP. Movers and shakers: influence of bacteriophages in shaping the mammalian gut microbiota. Gut Microbes. 2013;4(1):4–16.PubMedPubMedCentralCrossRef
8.
Bahra SM, Weidemann BJ, Castro AN, Walsh JW, deLeon O, Burnett CM, et al. Risperidone-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure. EBioMedicine. 2015;2(11):1725–34.PubMedCrossRef
9.
•• Voss JD, Leon JC, Dhurandhar NV, Robb FT. Pawnobiome: manipulation of the hologenome within one host generation and beyond. Front Microbiol. 2015;6:697. Discusses evolutionary perspective on manipulating host-microbe interactions and addresses evidence for the emergence of infectobesity in agriculture.PubMedPubMedCentralCrossRef
10.
Collinge J, Whitfield J, McKintosh E, Frosh A, Mead S, Hill AF, et al. A clinical study of kuru patients with long incubation periods at the end of the epidemic in Papua New Guinea. Philos Trans R Soc Lond B Biol Sci. 2008;363(1510):3725–39.PubMedPubMedCentralCrossRef
11.
Manuelidis L, Chakrabarty T, Miyazawa K, Nduom NA, Emmerling K. The kuru infectious agent is a unique geographic isolate distinct from Creutzfeldt-Jakob disease and scrapie agents. Proc Natl Acad Sci U S A. 2009;106(32):13529–34.PubMedPubMedCentralCrossRef
12.
Kim YS, Carp RI, Callahan SM, Wisniewski HM. Scrapie-induced obesity in mice. J Infect Dis. 1987;156(2):402–5.PubMedCrossRef
13.
Carp RI, Callahan SM, Sersen EA, Moretz RC. Preclinical changes in weight of scrapie-infected mice as a function of scrapie agent-mouse strain combination. Intervirology. 1984;21(2):61–9.PubMedCrossRef
14.
Kim YS, Carp RI, Callahan SM, Wisniewski HM. Adrenal involvement in scrapie-induced obesity. Proc Soc Exp Biol Med. 1988;189(1):21–7.PubMedCrossRef
15.
Strom A, Yutzy B, Kruip C, Ooms M, Schloot NC, Roden M, et al. Foodborne transmission of bovine spongiform encephalopathy to non-human primates results in preclinical rapid-onset obesity. PLoS One. 2014;9(8):e104343.PubMedPubMedCentralCrossRef
16.
Holznagel E, Yutzy B, Schulz-Schaeffer W, Kruip C, Hahmann U, Bierke P, et al. Foodborne transmission of bovine spongiform encephalopathy to nonhuman primates. Emerg Infect Dis. 2013;19(5):712–20.PubMedPubMedCentralCrossRef
17.
18.
Kralj D, Virović Jukić L, Stojsavljević S, Duvnjak M, Smolić M, Čurčić IB. Hepatitis C virus, insulin resistance, and steatosis. J Clin Transl Hepatol. 2016;4(1):66–75.PubMedPubMedCentralCrossRef
19.
20.
Xu MY, Cao B, Wang DF, Guo JH, Chen KL, Shi M, et al. Human adenovirus 36 infection increased the risk of obesity: a meta-analysis update. Medicine (Baltimore). 2015;94(51):e2357.CrossRef
21.
Yu Y, Maguire TG, Alwine JC. ChREBP, a glucose-responsive transcriptional factor, enhances glucose metabolism to support biosynthesis in human cytomegalovirus-infected cells. Proc Natl Acad Sci U S A. 2014;111(5):1951–6.PubMedPubMedCentralCrossRef
22.
Yu Y, Maguire TG, Alwine JC. Human cytomegalovirus infection induces adipocyte-like lipogenesis through activation of sterol regulatory element binding protein 1. J Virol. 2012;86(6):2942–9.PubMedPubMedCentralCrossRef
23.
Potena L, Frascaroli G, Grigioni F, Lazzarotto T, Magnani G, Tomasi L, et al. Hydroxymethyl-glutaryl coenzyme A reductase inhibition limits cytomegalovirus infection in human endothelial cells. Circulation. 2004;109(4):532–6.PubMedCrossRef
24.
Thai M, Graham NA, Braas D, Nehil M, Komisopoulou E, Kurdistani SK, et al. Adenovirus E4ORF1-induced MYC activation promotes host cell anabolic glucose metabolism and virus replication. Cell Metab. 2014;19(4):694–701.PubMedPubMedCentralCrossRef
25.
26.
Perry RJ, Peng L, Barry NA, Cline GW, Zhang D, Cardone RL, et al. Acetate mediates a microbiome-brain-β-cell axis to promote metabolic syndrome. Nature. 2016;534(7606):213–7.PubMedPubMedCentralCrossRef
27.
van Niekerk G, Engelbrecht AM. On the evolutionary origin of the adaptive immune system—the adipocyte hypothesis. Immunol Lett. 2015;164(2):81–7.PubMedCrossRef
28.
Chazenbalk G, Bertolotto C, Heneidi S, Jumabay M, Trivax B, Aronowitz J, et al. Novel pathway of adipogenesis through cross-talk between adipose tissue macrophages, adipose stem cells and adipocytes: evidence of cell plasticity. PLoS One. 2011;6(3):e17834.PubMedPubMedCentralCrossRef
29.
30.
Zhang LJ, Guerrero-Juarez CF, Hata T, Bapat SP, Ramos R, Plikus MV, et al. Innate immunity. Dermal adipocytes protect against invasive Staphylococcus aureus skin infection. Science. 2015;347(6217):67–71.PubMedPubMedCentralCrossRef
31.
Ioan-Facsinay A, Kwekkeboom JC, Westhoff S, Giera M, Rombouts Y, van Harmelen V, et al. Adipocyte-derived lipids modulate CD4+ T-cell function. Eur J Immunol. 2013;43(6):1578–87.PubMedCrossRef
32.
Ndumele CE, Nasir K, Conceiçao RD, Carvalho JA, Blumenthal RS, Santos RD. Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation. Arterioscler Thromb Vasc Biol. 2011;31(8):1927–32.PubMedPubMedCentralCrossRef
33.
Al Rifai M, Silverman MG, Nasir K, Budoff MJ, Blankstein R, Szklo M, et al. The association of nonalcoholic fatty liver disease, obesity, and metabolic syndrome, with systemic inflammation and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2015;239(2):629–33.PubMedPubMedCentralCrossRef
34.
Fernández-Real JM, Ferri MJ, Vendrell J, Ricart W. Burden of infection and fat mass in healthy middle-aged men. Obesity (Silver Spring). 2007;15(1):245–52.CrossRef
35.
Shang Q, Wang H, Song Y, Wei L, Lavebratt C, Zhang F, et al. Serological data analyses show that adenovirus 36 infection is associated with obesity: a meta-analysis involving 5739 subjects. Obesity (Silver Spring). 2014;22(3):895–900.CrossRef
36.
Yamada T, Hara K, Kadowaki T. Association of adenovirus 36 infection with obesity and metabolic markers in humans: a meta-analysis of observational studies. PLoS One. 2012;7(7):e42031.PubMedPubMedCentralCrossRef
37.
• Dhurandhar NV. A framework for identification of infections that contribute to human obesity. Lancet Infect Dis. 2011;11(12):963–9. Provides a framework for identifying and investigating infectobesity.PubMedCrossRef
38.
Sanlidag T, Akcali S, Vatansever S, Cicek C, Sayan M, Cakmakliogullari EK, et al. Investigation of adipogenic effects of human adenovirus serotypes 36 and 5 in a Colo-320 cell line. Futur Virol. 2013;8(6):617–22.CrossRef
39.
So PW, Herlihy AH, Bell JD. Adiposity induced by adenovirus 5 inoculation. Int J Obes (Lond). 2005;29(6):603–6.CrossRef
40.
Pasarica M, Shin AC, Yu M, Ou Yang HM, Rathod M, Jen KL, et al. Human adenovirus 36 induces adiposity, increases insulin sensitivity, and alters hypothalamic monoamines in rats. Obesity (Silver Spring). 2006;14(11):1905–13.CrossRef
41.
Dhurandhar NV, Israel BA, Kolesar JM, Mayhew G, Cook ME, Atkinson RL. Transmissibility of adenovirus-induced adiposity in a chicken model. Int J Obes Relat Metab Disord. 2001;25(7):990–6.PubMedCrossRef
42.
Whigham LD, Israel BA, Atkinson RL. Adipogenic potential of multiple human adenoviruses in vivo and in vitro in animals. Am J Physiol Regul Integr Comp Physiol. 2006;290(1):R190–4.PubMedCrossRef
43.
Dhurandhar NV, Kulkarni P, Ajinkya SM, Sherikar A. Effect of adenovirus infection on adiposity in chicken. Vet Microbiol. 1992;31(2-3):101–7.PubMedCrossRef
44.
Dhurandhar NV, Whigham LD, Abbott DH, Schultz-Darken NJ, Israel BA, Bradley SM, et al. Human adenovirus Ad-36 promotes weight gain in male rhesus and marmoset monkeys. J Nutr. 2002;132(10):3155–60.PubMed
45.
Dhurandhar NV, Dhurandhar EJ, Ingram DK, Vaughan K, Mattison JA. Natural infection of human adenovirus 36 in rhesus monkeys is associated with a reduction in fasting glucose 36. J Diabetes. 2014;6(6):614–6.PubMedPubMedCentralCrossRef
46.
Cakmakliogullari EK, Sanlidag T, Ersoy B, Akcali S, Var A, Cicek C. Are human adenovirus-5 and 36 associated with obesity in children? J Investig Med. 2014;62(5):821–4.PubMedCrossRef
47.
Dhurandhar NV, Kulkarni PR, Ajinkya SM, Sherikar AA, Atkinson RL. Association of adenovirus infection with human obesity. Obes Res. 1997;5(5):464–9.PubMedCrossRef
48.
Pasarica M, Mashtalir N, McAllister EJ, Kilroy GE, Koska J, Permana P, et al. Adipogenic human adenovirus Ad-36 induces commitment, differentiation, and lipid accumulation in human adipose-derived stem cells. Stem Cells. 2008;26(4):969–78.PubMedPubMedCentralCrossRef
49.
Floyd ZE, Stephens JM. Controlling a master switch of adipocyte development and insulin sensitivity: covalent modifications of PPARγ. Biochim Biophys Acta. 2012;1822(7):1090–5.PubMedPubMedCentralCrossRef
50.
Dhurandhar EJ, Dubuisson O, Mashtalir N, Krishnapuram R, Hegde V, Dhurandhar NV. E4orf1: a novel ligand that improves glucose disposal in cell culture. PLoS One. 2011;6(8):e23394.PubMedPubMedCentralCrossRef
51.
Dubuisson O, Dhurandhar EJ, Krishnapuram R, Kirk-Ballard H, Gupta AK, Hegde V, et al. PPARgamma-independent increase in glucose uptake and adiponectin abundance in fat cells. Endocrinology. 2011;152(10):3648–60.PubMedPubMedCentralCrossRef
52.
Dhurandhar NV. Insulin sparing action of adenovirus 36 and its E4orf1 protein. J Diabetes Complications. 2013;27(2):191–9.PubMedCrossRef
53.
Vangipuram SD, Yu M, Tian J, Stanhope KL, Pasarica M, Havel PJ, et al. Adipogenic human adenovirus-36 reduces leptin expression and secretion and increases glucose uptake by fat cells. Int J Obes (Lond). 2007;31(1):87–96.CrossRef
54.
Wang ZQ, Yu Y, Zhang XH, Floyd EZ, Cefalu WT. Human adenovirus 36 decreases fatty acid oxidation and increases de novo lipogenesis in primary cultured human skeletal muscle cells by promoting Cidec/FSP27 expression. Int J Obes (Lond). 2010;34(9):1355–64.CrossRef
55.
Lin WY, Dubuisson O, Rubicz R, Liu N, Allison DB, Curran JE, et al. Long-term changes in adiposity and glycemic control are associated with past adenovirus infection. Diabetes Care. 2013;36(3):701–7.PubMedPubMedCentralCrossRef
56.
Na HN, Nam JH. Adenovirus 36 as an obesity agent maintains the obesity state by increasing MCP-1 and inducing inflammation. J Infect Dis. 2012;205(6):914–22.PubMedCrossRef
57.
Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, Morel CR, Subramanian V, Mukundan L, et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature. 2007;447(7148):1116–20.PubMedPubMedCentralCrossRef
58.
Na HN, Park S, Jeon HJ, Kim HB, Nam JH. Reduction of adenovirus 36-induced obesity and inflammation by mulberry extract. Microbiol Immunol. 2014;58(5):303–6.PubMedCrossRef
59.
Bassols J, Moreno JM, Ortega F, Ricart W, Fernandez-Real JM. Characterization of herpes virus entry mediator as a factor linked to obesity. Obesity (Silver Spring). 2010;18(2):239–46.CrossRef
60.
Karjala Z, Neal D, Rohrer J. Association between HSV1 seropositivity and obesity: data from the National Health and Nutritional Examination Survey, 2007-2008. PLoS One. 2011;6(5):e19092.PubMedPubMedCentralCrossRef
61.
Vahdat K, Azizi F, Zandi K, Assadi M, Nabipour I. Chronic inflammation is correlated with percentage of body fat independent of the burden of infection. Inflammation. 2012;35(4):1322–9.PubMedCrossRef
62.
Schooling CM, Jones HE, Leung GM. Lifecourse infectious origins of sexual inequalities in central adiposity. Int J Epidemiol. 2011;40(6):1556–64.PubMedCrossRef
63.
Yu L, Liu P, Liu Z, Zhu W, Yan K, Chen Q, et al. p204-mediated innate antiviral responses in mouse adipose cells and their effects on cell functions. Immunol Cell Biol. 2015;93(2):147–57.PubMedCrossRef
64.
Park S, Bae JH. Probiotics for weight loss: a systematic review and meta-analysis. Nutr Res. 2015;35(7):566–75.PubMedCrossRef
65.
66.
Lei X, Piao X, Ru Y, Zhang H, Péron A, Zhang H. Effect of Bacillus amyloliquefaciens-based direct-fed microbial on performance, nutrient utilization, intestinal morphology and cecal microflora in broiler chickens. Asian-Australas J Anim Sci. 2015;28(2):239–46.PubMedPubMedCentralCrossRef
67.
Le O, Dart P, Harper K, Zhang D, Schofield B, Callaghan M, et al. Effect of probiotic Bacillus amyloliquefaciens strain H57 on productivity and the incidence of diarrhoea in dairy calves. Anim Prod Sci. 2016. doi:10.​1071/​AN15776. Accessed 22 Aug 2016.
68.
Balasubramanian B, Li T, Kim IH. Effects of supplementing growing-finishing pig diets with Bacillus spp. probiotic on growth performance and meat-carcass grade quality traits. R Bras Zootec. 2016;45(3):93–100.CrossRef
69.
Drissi F, Merhej V, Angelakis E, El Kaoutari A, Carrière F, Henrissat B, et al. Comparative genomics analysis of Lactobacillus species associated with weight gain or weight protection. Nutr Diabetes. 2014;4:e109.PubMedPubMedCentralCrossRef
70.
Gonzalez-Quintela A, Alonso M, Campos J, Vizcaino L, Loidi L, Gude F. Determinants of serum concentrations of lipopolysaccharide-binding protein (LBP) in the adult population: the role of obesity. PLoS One. 2013;8(1):e54600.PubMedPubMedCentralCrossRef
71.
Ukibe K, Miyoshi M, Kadooka Y. Administration of Lactobacillus gasseri SBT2055 suppresses macrophage infiltration into adipose tissue in diet-induced obese mice. Br J Nutr. 2015;114(8):1180–7.PubMedCrossRef
72.
73.
Reyes A, Wu M, McNulty NP, Rohwer FL, Gordon JI. Gnotobiotic mouse model of phage-bacterial host dynamics in the human gut. Proc Natl Acad Sci U S A. 2013;110(50):20236–41.PubMedPubMedCentralCrossRef
74.
Manuelidis L. A 25 nm virion is the likely cause of transmissible spongiform encephalopathies. J Cell Biochem. 2007;100(4):897–915.PubMedCrossRef
75.
Botsios S, Manuelidis L. CJD and scrapie require agent-associated nucleic acids for infection. J Cell Biochem. 2016;117(8):1947–58.PubMedCrossRef
76.
77.
Strom A, Yutzy B, Kruip C, Völker I, Schloot NC, Roden M, et al. Spontaneous obesity-linked type 2 diabetes in the absence of islet amyloid in a cynomolgus monkey infected with bovine spongiform encephalopathy. Vet Pathol. 2013;50(5):909–13.PubMedCrossRef
78.
Spudich S, Mastrianni JA, Wrensch M, Gabizon R, Meiner Z, Kahana I, et al. Complete penetrance of Creutzfeldt-Jakob disease in Libyan Jews carrying the E200K mutation in the prion protein gene. Mol Med. 1995;1(6):607–13.PubMedPubMedCentral
79.
80.
81.
82.
Carter JK, Ow CL, Smith RE. Rous-associated virus type 7 induces a syndrome in chickens characterized by stunting and obesity. Infect Immun. 1983;39(1):410–22.PubMedPubMedCentral
83.
Lyons MJ, Faust IM, Hemmes RB, Buskirk DR, Hirsch J, Zabriskie JB. A virally induced obesity syndrome in mice. Science. 1982;216(4541):82–5.PubMedCrossRef
84.
Satterfield D, Keltner JL, Morrison TL. Psychosocial aspects of strabismus study. Arch Ophthalmol. 1993;111(8):1100–5.PubMedCrossRef
85.
Tomiyama AJ, Mann T. If shaming reduced obesity, there would be no fat people. Hastings Cent Rep. 2013;43(3):4–5.PubMedCrossRef
86.
Jackson SE, Beeken RJ, Wardle J. Perceived weight discrimination and changes in weight, waist circumference, and weight status. Obesity (Silver Spring). 2014;22(12):2485–8.
87.
Provencher V, Bégin C, Tremblay A, Mongeau L, Corneau L, Dodin S, et al. Health-at-every-size and eating behaviors: 1-year follow-up results of a size acceptance intervention. J Am Diet Assoc. 2009;109(11):1854–61.PubMedCrossRef
88.
89.
Sanderson SC, Persky S, Michie S. Psychological and behavioral responses to genetic test results indicating increased risk of obesity: does the causal pathway from gene to obesity matter? Public Health Genomics. 2010;13(1):34–47.PubMedCrossRef
90.
91.
Christakis NA, Fowler JH. The spread of obesity in a large social network over 32 years. N Engl J Med. 2007;357(4):370–9.PubMedCrossRef
92.
Ludwig DS, Friedman MI. Increasing adiposity: consequence or cause of overeating? JAMA. 2014;311(21):2168.CrossRef
93.
Field AE, Camargo Jr CA, Ogino S. The merits of subtyping obesity: one size does not fit all. JAMA. 2013;310(20):2147–8.PubMedCrossRef
94.
Kühnen P, Clément K, Wiegand S, Blankenstein O, Gottesdiener K, Martini LL, et al. Proopiomelanocortin deficiency treated with a melanocortin-4 receptor agonist. N Engl J Med. 2016;375(3):240–6.PubMedCrossRef
95.
Gratzl R, Sodeck G, Platzer P, Jäger W, Graf J, Pollak A, et al. Treatment of toxoplasmosis in pregnancy: concentrations of spiramycin and neospiramycin in maternal serum and amniotic fluid. Eur J Clin Microbiol Infect Dis. 2002;21(1):12–6.PubMedCrossRef
96.
97.
Sabin MA, Burgner D, Atkinson RL, Pei-Lun Lee Z, Magnussen CG, Cheung M, et al. Longitudinal investigation of adenovirus 36 seropositivity and human obesity: the Cardiovascular Risk in Young Finns study. Int J Obes (Lond). 2015;39(11):1644–50.
98.
Trovato GM, Martines GF, Trovato FM, Pirri C, Pace P, Garozzo A, et al. Adenovirus-36 seropositivity enhances effects of nutritional intervention on obesity, bright liver, and insulin resistance. Dig Dis Sci. 2012;57(2):535–44.PubMedCrossRef
99.
Voss JD, Burnett DG, Olsen CH, Haverkos HW, Atkinson RL. Adenovirus 36 antibodies associated with clinical diagnosis of overweight/obesity but not BMI gain: a military cohort study. J Clin Endocrinol Metab. 2014;99(9):E1708–12.PubMedPubMedCentralCrossRef
100.
Brown AW, Bohan Brown MM, Allison DB. Belief beyond the evidence: using the proposed effect of breakfast on obesity to show 2 practices that distort scientific evidence. Am J Clin Nutr. 2013;98(5):1298–308.PubMedPubMedCentralCrossRef
101.
Xu GJ, Kula T, Xu Q, Li MZ, Vernon SD, Ndung’u T, et al. Viral immunology. Comprehensive serological profiling of human populations using a synthetic human virome. Science. 2015;348(6239):aaa0698.PubMedPubMedCentralCrossRef
102.
Dutilh BE, Cassman N, McNair K, Sanchez SE, Silva GG, Boling L, et al. A highly abundant bacteriophage discovered in the unknown sequences of human faecal metagenomes. Nat Commun. 2014;5:4498.PubMedPubMedCentralCrossRef
103.
Pavela G, Wiener H, Fontaine KR, Fields DA, Voss JD, Allison DB. Packet randomized experiments for eliminating classes of confounders. Eur J Clin Investig. 2015;45(1):45–55.CrossRef
104.
Berry SM, Connor JT, Lewis RJ. The platform trial: an efficient strategy for evaluating multiple treatments. JAMA. 2015;313(16):1619–20.PubMedCrossRef
105.
Van Damme P, Meijer CJ, Kieninger D, Schuyleman A, Thomas S, Luxembourg A, et al. A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men. Vaccine. 2016;34(35):4205–12.PubMedCrossRef
106.
Na HN, Nam JH. Proof-of-concept for a virus-induced obesity vaccine; vaccination against the obesity agent adenovirus 36. Int J Obes (Lond). 2014;38(11):1470–4.
107.
Nam JH, Na HN, Atkinson RL, Dhurandhar NV. Genomic stability of adipogenic human adenovirus 36. Int J Obes (Lond). 2014;38(2):321–4.CrossRef
108.
Paris R, Kuschner RA, Binn L, Thomas SJ, Colloca S, Nicosia A, et al. Adenovirus type 4 and 7 vaccination or adenovirus type 4 respiratory infection elicits minimal cross-reactive antibody responses to nonhuman adenovirus vaccine vectors. Clin Vaccine Immunol. 2014;21(5):783–6.PubMedPubMedCentralCrossRef
109.
Zeevi D, Korem T, Zmora N, Israeli D, Rothschild D, Weinberger A, et al. Personalized nutrition by prediction of glycemic responses. Cell. 2015;163(5):1079–94.PubMedCrossRef
Metadata
Title
Viral Infections and Obesity
Authors
Jameson D. Voss
Nikhil V. Dhurandhar
Publication date
01-03-2017
Publisher
Springer US
Published in
Current Obesity Reports / Issue 1/2017
Electronic ISSN: 2162-4968
DOI
https://doi.org/10.1007/s13679-017-0251-1

Other articles of this Issue 1/2017

Current Obesity Reports 1/2017 Go to the issue

Etiology of Obesity (T Gill, Section Editor)

Endocrine Disruptors and Obesity

Etiology of Obesity (T Gill, Section Editor)

Portion Size: Latest Developments and Interventions

Psychological Issues (M Hetherington and V Drapeau, Section Editors)

Understanding Food Fussiness and Its Implications for Food Choice, Health, Weight and Interventions in Young Children: The Impact of Professor Jane Wardle

Etiology of Obesity (T Gill, Section Editor)

What Is Driving Obesity? A Review on the Connections Between Obesity and Motorized Transportation

Psychological Issues (M Hetherington and V Drapeau, Section Editors)

Genetic Testing for Obesity: Implications and Challenges

Psychological Issues (M Hetherington and V Drapeau, Section Editors)

Restrained Eating and Food Cues: Recent Findings and Conclusions
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits